SIRTURO® Is the First Medication for Pulmonary MDR-TB With a Novel Mechanism of Action in Over 40 Years
- SIRTURO® is the first anti-TB drug to interfere with bacterial
energy metabolism.
- SIRTURO® specifically inhibits
mycobacterial ATP (adenosine 5'-triphosphate) synthase, by binding to
subunit c of the enzyme that is essential for the generation of energy
in Mycobacterium tuberculosis.
Download a comprehensive resource on SIRTURO® (bedaquiline) tablets